Exopharm Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of EX1?
Owner Type	Number of Shares	Ownership Percentage
Institutions	19,870,333	4.52%
Private Companies	40,036,213	9.11%
Individual Insiders	80,411,184	18.3%
General Public	299,105,336	68.1%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 179.5%.

Top Shareholders

Top 23 shareholders own 31.93% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
6.43%	Ian Dixon	28,258,627	AU$310.8k	0%	no data
4.39%	Carl Charalambous	19,287,557	AU$212.2k	265%	no data
3%	Zessham Pty Ltd	13,200,000	AU$145.2k	1,000%	no data
2.67%	Dixson Trust Pty Limited, Asset Management Arm	11,712,000	AU$128.8k	851%	0.03%
1.86%	Canary Capital Pty Ltd	8,158,333	AU$89.7k	0%	39.23%
1.71%	Harlund Investments Pty Ltd	7,500,000	AU$82.5k	549%	no data
1.31%	Paul Madden	5,750,000	AU$63.2k	0%	no data
1.09%	Wolseley Road 1 Pty Limited	4,800,000	AU$52.8k	380%	no data
1.08%	Huon Pine Pty Ltd	4,752,831	AU$52.3k	0%	no data
0.91%	Oldview Enterprises Pty Ltd	4,000,000	AU$44.0k	131%	no data
0.91%	Paul Cozzi	4,000,000	AU$44.0k	100%	no data
0.86%	Prinsloo Dube	3,780,000	AU$41.6k	0%	no data
0.85%	Celtic Finance Corp Pty Ltd	3,750,000	AU$41.2k	0%	no data
0.85%	Carlo Bellini	3,750,000	AU$41.2k	0%	no data
0.85%	Susan McMahon	3,750,000	AU$41.2k	618%	no data
0.85%	Michael Mcmahon	3,750,000	AU$41.2k	618%	no data
0.8%	Ann Hatch	3,525,000	AU$38.8k	0%	no data
0.46%	Chara Brothers Pty Ltd	2,033,382	AU$22.4k	0%	no data
0.43%	Andrew Fay	1,875,000	AU$20.6k	56.3%	no data
0.43%	Narelle Fay	1,875,000	AU$20.6k	0%	no data
0.17%	Jason Watson	760,000	AU$8.4k	0%	no data
0.0068%	Elizabeth McGregor	30,000	AU$330.1	0%	no data
0.0046%	Clarke Barlow	20,000	AU$219.9	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/12/30 05:16
End of Day Share Price	2023/10/02 00:00
Earnings	2023/06/30
Annual Earnings	2023/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Exopharm Limited is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution